EYE
Get informed when a big investor buys or sells
+ FollowOvervalued by 69.1% based on the discounted cash flow analysis.
| Market cap | $1.57 Billion |
|---|---|
| Enterprise Value | $2.24 Billion |
| Dividend Yield | $- (-) |
| Earnings per Share | $0.37 |
| Beta | 1.04 |
| Outstanding Shares | 79,655,000 |
| P/E Ratio | 33.45 |
|---|---|
| PEG | 27.92 |
| Price to Sales | 0.8 |
| Price to Book Ratio | 1.83 |
| Enterprise Value to Revenue | 1.11 |
| Enterprise Value to EBIT | 28.35 |
| Enterprise Value to Net Income | 48 |
| Total Debt to Enterprise | 0.33 |
| Debt to Equity | 0.83 |
No data
Market sentiment based on institutional option activity.
| Put/Call Ratio | 0.0000▼ 100.69% |
|---|---|
| Total Calls | -▼ 100.00% |
| Total Puts | -▼ 100.00% |
Holdings and activity of institutional investors.
| Ownership % | 0.16%▼ 120.30% |
|---|---|
| Total Invested | $2.39M▼ 99.90% |
| Investors Holding | 5▼ 261.00% |
No data
Jurisdiction over Medicare and Medicaid vision coverage and trade tariffs on imported frames and lenses.
Regulates the FDA, which oversees contact lenses and frames as medical devices, and manages healthcare labor regulations.